InventisBio (SH:688382) Xin Lang Cai Jing·2025-09-24 02:29Core Viewpoint - Yifang Bio has experienced significant stock price fluctuations, with a year-to-date increase of 151.05%, but a recent decline over the past few trading days [1][2] Company Overview - Yifang Bio is located in the Shanghai Free Trade Zone and was established on January 11, 2013, with its IPO on July 25, 2022. The company focuses on the research, production, and sales of innovative drugs, with 100% of its main business revenue coming from technology licensing and cooperation [1] Financial Performance - For the first half of 2025, Yifang Bio reported revenue of 19.16 million yuan, a year-on-year increase of 28.85%. However, the net profit attributable to shareholders was -119 million yuan, reflecting a year-on-year increase of 44.25% in losses [2] Stock Market Activity - As of September 24, Yifang Bio's stock price was 33.39 yuan per share, with a market capitalization of 19.31 billion yuan. The stock has seen a trading volume of 120 million yuan and a turnover rate of 0.88% [1] - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent instance on July 11, where it recorded a net purchase of 68.87 million yuan [1] Shareholder Information - As of June 30, 2025, Yifang Bio had 9,790 shareholders, a decrease of 7.28% from the previous period. The average number of circulating shares per shareholder increased by 7.85% to 40,990 shares [2] - Notable institutional shareholders include Huatai-PB Innovation Medicine Mixed A and others, with significant changes in holdings among the top ten circulating shareholders [2]